Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Tesetaxel Plus Checkpoint Inhibitors Among Patients With Metastatic Triple-Negative Breast Cancer
- IV NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting
- Breast Cancer Mortality Rates Higher in Men Than in Women
- Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer
- Fulvestrant + Vistusertib vs Fulvestrant + Everolimus vs Fulvestrant Alone in HR+ Metastatic Breast Cancer
- Fulvestrant + Vistusertib vs Fulvestrant + Everolimus vs Fulvestrant Alone in HR+ Metastatic Breast Cancer
- Home-Based Exercise and Weight Loss Programs Do Not Impact Breast Cancer-Related Lymphedema Outcomes Among Overweight Breast Cancer Survivors
- Neoadjuvant Letrozole + Taselisib vs Letrozole + Placebo in Postmenopausal Women With ER-Positive, HER2-Negative, Early-Stage Breast Cancer
- NEPA for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea/Vomiting
- Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer